Novo and Merck Group have exited ObsEva in an offering that involved the reproductive health treatment developer floating in the middle of its range.
Switzerland-based reproductive health company ObsEva raised approximately $96.8m on Wednesday when it priced an initial public offering that will allow pharmaceutical firms Novo and Merck Group to exit.
ObsEva issued 6.45 million shares on Nasdaq priced at $15 each, right in the middle of the $14 to $16 range it set last week.
Joint bookrunners Credit Suisse Securities, Jefferies and Leerink Partners have the 30-day option to buy almost 970,000 more shares, which would increase the size of…
